DUBLIN,
Nov. 20,
2024 /PRNewswire/ -- Theravance Biopharma, Inc.
(NASDAQ: TBPH) will participate in a Fireside Chat at the
7th Annual Evercore HealthCONx Conference on
Tuesday, December 3 at 11:15 am EST (8:15 am
PST/4:15 pm GMT) and will be
hosting in-person meetings with the investment community at the
conference.
Webcast of the event may be accessed by visiting
Theravance.com, under the Investors section, Events and
Presentations. Replay of the webcast will be archived on the
Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver
Medicines that Make a Difference® in people's
lives. In pursuit of its purpose, Theravance Biopharma leverages
decades of expertise, which has led to the development of
FDA-approved YUPELRI® (revefenacin) inhalation solution
indicated for the maintenance treatment of patients with chronic
obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage
investigational once-daily norepinephrine reuptake inhibitor in
development for symptomatic neurogenic orthostatic hypotension
(nOH) in patients with Multiple System Atrophy (MSA), has the
potential to be a first in class therapy effective in treating a
constellation of cardinal symptoms in MSA patients. The Company is
committed to creating/driving shareholder value.
For more information, please visit
www.theravance.com.
THERAVANCE BIOPHARMA®,
THERAVANCE® and the Cross/Star logo are registered
trademarks of the Theravance Biopharma group of companies
(in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan
Specialty L.P., a Viatris company. Trademarks, trade names or
service marks of other companies appearing in this press release
are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302311022.html
SOURCE Theravance Biopharma, Inc.